Twist Bioscience Corporation (BIT:1TWST)
Italy · Delayed Price · Currency is EUR | Market Cap | 6.42B +335.0% |
| Revenue (ttm) | 377.95M +19.2% |
| Net Income | -119.67M |
| EPS | -1.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20 |
| Open | 110.70 |
| Previous Close | 107.90 |
| Day's Range | 110.70 - 110.70 |
| 52-Week Range | 19.50 - 110.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Twist Bioscience
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial numbers in USD Financial StatementsNews
Twist Bioscience price target raised to $115 from $85 at Piper Sandler
Piper Sandler raised the firm’s price target on Twist Bioscience (TWST) to $115 from $85 and keeps an Overweight rating on the shares. The firm cites a higher long-term revenue…
Twist Bioscience 3.125M share Spot Secondary priced at $96.00
The deal size was increased to $300M in common stock from $250M in common stock. Goldman Sachs, William Blair, Leerink and Guggenheim acted as joint book running managers for the…
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten ...
Twist Bioscience announces $250M common stock offering
Twist Bioscience (TWST) Corporation announced the commencement of an underwritten public offering of $250M of shares of its common stock. All of the shares of common stock to be sold…
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten pub...
Twist Bioscience announces inducement grants under Nasdaq listing rule
As required by the rules of the Nasdaq Stock Market, Twist Bioscience (TWST) announced that a total of 44,434 restricted stock units will be granted to 24 recently hired individuals,…
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...
Twist Bioscience price target raised to $115 from $113 at Baird
Baird raised the firm’s price target on Twist Bioscience (TWST) to $115 from $113 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Twist Bioscience price target raised to $115 from $89 at TD Cowen
TD Cowen analyst Brendan Smith raised the firm’s price target on Twist Bioscience (TWST) to $115 from $89 and keeps a Buy rating on the shares. A Q3 revenue beat…
Twist Bioscience Earnings Call Transcript: Q3 2026
Record Q3 revenue grew 23% year-over-year, driven by strong demand in AI-enabled drug discovery and diagnostics. Raised fiscal 2026 guidance, expecting 21% annual growth and adjusted EBITDA breakeven in Q4. Triple-digit AI order growth is projected to continue into 2027.
Twist Bioscience Slides: Q3 2026
Twist Bioscience has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 3, 2026.
Twist Bioscience Earnings release: Q3 2026
Twist Bioscience released its Q3 2026 earnings on August 3, 2026, summarizing the period's financial results.
Twist Bioscience Quarterly report: Q3 2026
Twist Bioscience has published its Q3 2026 quarterly earnings report on August 3, 2026.
Twist Bioscience raises FY26 revenue view $456M-$457M from $442M-$447M
Consensus $444.69M. Sees gross margin above 52%.
Twist Bioscience sees Q4 revenue $123M-$124M, consensus $117.42M.
Sees achieving adjusted EBITDA breakeven.
Twist Bioscience reports Q3 EPS (56c) vs. 33c last year
Reports Q3 revenue $118.4M, consensus $114.54M. “We continued our pattern of strong growth, reporting our fourteenth consecutive quarter of growth and exceeding guidance with revenue for the third qua...
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...
Twist Bioscience price target raised to $110 from $80 at Leerink
Leerink analyst Puneet Souda raised the firm’s price target on Twist Bioscience (TWST) to $110 from $80 and keeps an Outperform rating on the shares.
Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the ...
Twist Bioscience price target raised to $120 from $90 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Twist Bioscience (TWST) to $120 from $90 and keeps a Buy rating on the shares. The firm updated its model…
Twist Bioscience downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Twist Bioscience (TWST) to In Line from Outperform with a price target of $102, up from $66. Twist has been one of the best performers in life…
Twist Bioscience price target raised to $107 from $60 at Guggenheim
Guggenheim raised the firm’s price target on Twist Bioscience (TWST) to $107 from $60 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select…
Twist Bioscience price target raised to $95 from $65 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience (TWST) to $95 from $65 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Ozempic Linked To Lower Risk Of Violence In New Study
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J...
Twist Bioscience Transcript: 46th Annual William Blair Growth Stock Conference
The company leverages silicon-based DNA synthesis to deliver rapid innovation, automation, and cost reductions, driving strong revenue growth and expanding its addressable market. With a diversified product portfolio and customer base, it targets adjusted EBITDA breakeven by Q4 and plans further expansion into mRNA and gene therapies.